uniQure N.V. shares increased by 7.83% as the stock reached a 5-day high, reflecting a positive market reaction.
This rise comes amid recent news of positive results from uniQure's Phase I/II study of AMT-130 for Huntington’s disease, which demonstrated a 75% slowing of disease progression at high doses. Despite the positive trial results, the stock has faced significant challenges following the FDA's rejection of the Biologics License Application (BLA) for AMT-130, leading to heightened investor scrutiny and concerns about the company's future.
The implications of the recent trial results may provide some optimism for investors, but the ongoing regulatory hurdles and market sentiment will likely continue to influence the stock's performance in the near term.
Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 49.88 USD with a low forecast of 33.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 49.88 USD with a low forecast of 33.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.020
Low
33.00
Averages
49.88
High
70.00
Current: 23.020
Low
33.00
Averages
49.88
High
70.00
Barclays
Equal Weight
initiated
$31
2026-01-27
New
Reason
Barclays
Price Target
$31
AI Analysis
2026-01-27
New
initiated
Equal Weight
Reason
Barclays initiated coverage of uniQure with an Equal Weight rating and $31 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Stifel
Buy
to
Buy
downgrade
$50 -> $40
2025-12-11
Reason
Stifel
Price Target
$50 -> $40
2025-12-11
downgrade
Buy
to
Buy
Reason
Stifel lowered the firm's price target on uniQure to $40 from $50 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QURE
Unlock Now
Mizuho
Uy Ear
Outperform
to
NULL
downgrade
$60 -> $33
2025-12-08
Reason
Mizuho
Uy Ear
Price Target
$60 -> $33
2025-12-08
downgrade
Outperform
to
NULL
Reason
Mizuho analyst Uy Ear lowered the firm's price target on uniQure to $33 from $60 and keeps an Outperform rating on the shares after lowering the firm's view of the probability of success and pushing out its expected launch year for AMT-130 by one year following the company announcing that the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 for Huntington's disease are currently unlikely to provide the primary evidence to support a Biologics License Application.
Leerink
Outperform
to
NULL
downgrade
$68 -> $60
2025-11-10
Reason
Leerink
Price Target
$68 -> $60
2025-11-10
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on uniQure to $60 from $68 and keeps an Outperform rating on the shares following quarterly results and earnings call, which was "unsurprisingly" focused on the regulatory path for AMT-130 in Huntington's disease. Leerink acknowledges the "surprise" last week when uniQure sounded the alarm and disclosed that the FDA no longer agreed that the data from the Phase 1/2 studies and prespecified analyses vs. an external control may be adequate to provide primary evidence in support of a BLA submission. On the call today, uniQure emphasized that this FDA reversal does not change their data for AMT-130 in HD that support real and serious disease modification. While this news has made timing of a BLA submission uncertain, the company plans to urgently engage with the FDA to discuss next steps, beginning with the formal meeting minutes.
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
